Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 100,000 shares at $55.46 ($5.5M) on 2015-01-13, disclosed to the SEC on 2015-01-15.
Open-market sale of $5.5M AAVL by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| [AAVL] | SELL | 2015-06-08 | $200K | — | Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-18 | $798K | — | Filing → |